The Ohio State University and Battelle Partner to Establish new NeuroTech Institute to Help Advance Neurolgical Research and Treatment


An independent, state-of-the-art neurotechnology accelerator with a focus on treatments for patients with neurological illnesses has been established in collaboration between The Ohio State University and Battelle.

According to the United Nations, 1 in 6 people globally have neurological problems. Many people’s health cannot be restored by current treatments, and potential novel medicines face a protracted and difficult journey to market.

The development will proceed more quickly thanks to the new NeuroTech Institute (NTI). NTI is a biotechnology accelerator that houses three distinct projects with a focus on neural communication disorders, the neural genome, and the brain’s neural network. It is already developing new technology to assist people who have suffered spinal cord injuries and are paralysed.

Using a collaborative approach to science, NTI brings together clinicians, engineers, and patient advocates to pioneer novel treatments. It is the result of years of planning by Ohio State and Battelle.

The breadth of experience of the already existing faculty across Ohio State and Battelle will increase as a result of NTI’s recruitment of academics, researchers, and support personnel.

“This new institute complements Ohio State’s efforts to build new opportunities for interdisciplinary research, translation and partnerships and accelerate solutions for patients with neurological disorders,”

Peter Mohler, PhD, Vice President for Research at Ohio State


“By partnering with Ohio State and combining our resources, skills and vision we will be able to bring speed, creativity and expertise to bring world-changing neurotechnology solutions. Ohio State brings breakthrough foundational science, Battelle brings advanced development and applied science and technology, and the Institute brings the accelerator and philanthropic elements.”

Matt Vaughan, Battelle Executive Vice President of Applied Science and Technology

The first CEO of NTI was chosen to be Tim Lucas, MD, PhD, MHCI, professor of neurological surgery at Ohio State’s College of Medicine. Lucas brings to the new centre four sizable grants from the National Institutes of Health as well as sponsored research agreements from the public and private sectors.

“At NTI, our mission is to restore quality of life to those suffering from neurological diseases, such as dementia, epilepsy, and addiction. Through our innovations, we will ensure that patients benefit from new treatments as quickly as possible,”

Tim Lucas, MD, PhD, MHCI, professor of neurological surgery

Next Post

Pfizer Completes Acquisition of Global Blood Therapeutics

Pfizer now has access to a premier sickle cell disease portfolio and pipeline, which has the potential to address pressing needs in a patient population that is underserved. Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical business committed to the discovery, development, and delivery of game-changing therapies that give hope to […]